CORRECTED-Actelion raises full-year guidance
(Corrects day of the week to Thursday)
ZURICH, July 18 (Reuters) - Actelion, Europe's largest biotech company lifted its full-year guidance on Thursday and now expects to return to growth in 2013 boosted by strong sales of its mainstay product and benefits from its cost-savings programme.
Actelion said it now expects core earnings to cross into the double-digit percentage range for 2013. Due to the faster growth in 2012 and 2013, Actelion forecast stable earnings in 2014 and growth in at least the single-digit range in 2015.
It had previously forecast stable core earnings in 2013 in local currencies, followed by a return to growth in 2014 and double digit percentage growth in 2015.
Sales of its main product Tracleer, a treatment for pulmonary arterial hypertension (PAH) rose 2 percent to 766.9 million Swiss francs ($812.5 million) in the first half, while net profit for the period was 199.5 million francs. ($1 = 0.9439 Swiss francs) (Reporting by Caroline Copley)
- South Korea recovers first bodies from inside sunken ferry |
- Japan expands army footprint for first time in 40 years, risks angering China
- Special Report: How the U.S. made its Putin problem worse
- Vice-principal of South Korea school in ferry disaster commits suicide |
- Mediator heads to east Ukraine, seeking surrenders |